Author

H.-G. Rammensee

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Organism:chicken / avian· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

M. Ghosh· 4 shared S. Stevanovic· 4 shared A. Marcu· 2 shared A. Nelde· 2 shared H. Schuster· 2 shared M. Denk· 2 shared M. Gauger· 2 shared A. Königsrainer· 1 shared

Activity by Year

2019-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Ghosh

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Differential host response to a herpesvirus: Mareks disease virus peptides on chicken MHC class II molecules are derived from only a few genes and illustrate a new mode of peptide binding

S. Halabi, M. Ghosh, S. Stevanovic, H.-G. Rammensee, L. D. Bertzbach, B. B. Kaufer, M. C. Moncrieffe, B. Kaspers, S. Härtle, J. Kaufman

The paper identifies that Mareks disease virus peptides presented by chicken MHC class II molecules come from only four genes, revealing a new peptide binding mode and explaining MHC-driven resistance to the virus.

bioRxiv · Nov 27, 2020Immunology

An innovative approach for HLA typing, molecular tumor testing and the validation of tumor exclusive antigens

M. Ghosh, L. Bichmann, J. Scheid, G. Gueler, H. Schuster, M. Di Marco, A. Marcu, M. Beyer, A. Nelde, L. K. Freudenmann, L. Muehlenbruch, M. W. Loeffler, O. Kohlbacher, H.-G. Rammensee, S. Stevanovic

The paper describes an innovative approach for HLA typing, molecular tumor testing, and validation of tumor-exclusive antigens but has been withdrawn by the authors.

bioRxiv · Jun 5, 2020 · PreprintImmunology

Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture

M. Ghosh, M. Gauger, M. Denk, H.-G. Rammensee, S. Stevanovic

The paper develops a simple method to extract and analyze peptides from a water-in-oil emulsion to verify equal distribution in a vaccination syringe.

bioRxiv · Jan 22, 2020 · PreprintPharmacology & Toxicology

Validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands suitable for pharmaceutical therapies

M. Ghosh, M. Gauger, A. Marcu, A. Nelde, M. Denk, H. Schuster, H.-G. Rammensee, S. Stevanovic

The paper validates an LC-MS/MS immunopeptidomics assay for identifying HLA class I ligands suitable for personalized immunotherapy.

bioRxiv · Oct 29, 2019Immunology

Short-term oxaliplatin exposure according to established hyperthermic intraperitoneal chemotherapy (HIPEC) protocols lacks effectiveness in vitro and ex vivo

M. W. Löffler, N. Seyfried, M. Burkard, B. Oswald, A. Tolios, C. Yurttas, F. Herster, J. Kauer, T. Jäger, K. Thiel, S. P. Haen, H.-G. Rammensee, S. Venturelli, M. Schwab, A. Königsrainer, S. Beckert

This study shows that oxaliplatin-containing solutions during HIPEC protocols are ineffective in vitro and ex vivo, with low cytotoxicity and cell shrinkage observed.

bioRxiv · Jul 31, 2019 · PreprintPharmacology & Toxicology